Lung Cancer Therapeutics Market
Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report by Cancer Type (Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC)), by Therapy Type (Targeted Therapy, Immunotherapy, Chemotherapy, Radiation Therapy, and Others), and by End User (Hospitals, Cancer Research Institutes, Specialty Clinics, and Homecare Settings) Forecast Period (2025-2035)
Industry Overview
Lung cancer therapeutics market was valued at $37,500 million in 2024 and is projected to reach $109,787 million by 2035, growing at a CAGR of 10.3% from 2025 to 2035. Regulatory frameworks drive market growth by promoting rapid clinical development, prioritizing novel lung cancer treatments, and facilitating quicker patient access. For instance, in August 2024, GSK received Breakthrough Therapy Designation from the US FDA for its B7-H3-targeted antibody-drug conjugate for treating relapsed or refractory extensive-stage small-cell lung cancer. The designation aims to expedite the development and review of drugs with the potential to treat serious conditions where preliminary clinical evidence may indicate substantial improvement over currently available therapy. ES-SCLC is an aggressive and difficult-to-treat cancer with limited treatment options.
Market Dynamics
Rising Lung Cancer Incidence & Mortality
The increasing global prevalence of lung cancer, particularly among the aging population, is boosting the need for effective treatments and market growth. According to the American Cancer Society, in January 2025, it projects there will be approximately 226,650 new lung cancer cases in the US, with 110,680 affecting men and 115,970 affecting women. Additionally, lung cancer is expected to result in about 124,730 deaths, comprising 64,190 men and 60,540 women. Lung cancer is most prevalent among older adults, with the majority of diagnoses occurring in individuals aged 65 or older, and the average age at diagnosis is around 70.
Advancements in Immuno-oncology and Targeted Therapies
New immunotherapies, such as immune checkpoint inhibitors and bispecific T-cell engagers, are revolutionizing lung cancer treatment by targeting cancer cells, boosting market growth. For instance, in January 2025, Amgen granted a conditional marketing authorization for IMDYLLTRA for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression after at least two prior lines of therapy, including platinum-based chemotherapy. The authorization is based on the results of a Phase 2 open-label, multicentre study that evaluated tarlatamab in patients with ES-SCLC who had failed two or more prior lines of treatment. IMDYLLTRA is a bispecific DLL3-directed CD3 T-cell engager.
Market Segmentation
- Based on the cancer type, the market is segmented into non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC).
- Based on the method of control, the market is segmented into targeted therapy, immunotherapy, chemotherapy, radiation therapy, and others.
- Based on the application, the market is segmented into hospitals, cancer research institutes, specialty clinics, and home care settings.
Immunotherapy: A Key Segment in Market Growth
The increasing application of immunotherapy, in the form of immune checkpoint inhibitors, as a first-line treatment option for advanced NSCLC cases and early-stage disease settings is fueling market growth. According to the National Center for Biotechnology Information, in February 2023, lung cancer was the leading cause of cancer-related morbidity and mortality worldwide, and NSCLC accounts for about 85% of the cases. The arrival of immunotherapy has greatly changed the treatment of NSCLC, especially with the introduction of immune checkpoint inhibitors (ICIs) against PD?1 or PD?L1. The therapies, which have become clinically approved, are now increasingly being used in both early and advanced disease. Clinical trials, such as immune neoadjuvant and postoperative adjuvant therapy, are ongoing, shaping future models of treatment and helping to advance perioperative lung cancer treatment.
Regional Outlook
The global lung cancer therapeutics market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
Demand for Precision Medicine in Asia-Pacific
The precision medicine market is expanding owing to the growing demand for personalized therapies utilizing molecular profiling, including NGS testing as a clinical standard. For instance, in March 2025, the LuNGS Alliance launched free lung NGS biomarker testing for lung cancer patients in India, backed by AstraZeneca, Pfizer, and Roche, promoting precision oncology as an accessible, affordable treatment option. 4baseCare's TARGT First Solid test analyzes 72 mutated genes to identify biomarkers for personalized cancer treatments. This test detects FDA and NCCN therapies, enhancing patient outcomes and making cancer care more accessible through the LuNGS Alliance's zero-cost biomarker testing.
North America Region Dominates the Market with Major Share
North America holds a significant share, owing to the market growth is primarily driven by the growing use of combination therapies, especially in advanced and resistant cancers, as they enhance survival outcomes. For instance, in February 2024, Tagrisso was approved in the US for treating adult patients with advanced or metastatic EGFR-mutated NSCLC. Furthermore, a chemotherapy-administered cancer treatment, after a priority review. The study found that Tagrisso reduced disease progression or death by 38% compared to Tagrisso monotherapy. The median progression-free survival was 25.5 months for patients treated with Tagrisso plus chemotherapy, an 8.8-month improvement from Tagrisso monotherapy.
Market Players Outlook
The major companies operating in the global lung cancer therapeutics market include AstraZeneca PLC, Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Co., Novartis AG, and Eli Lilly and Co., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In January 2025, ImmunityBio partnered with BeiGene to conduct a Phase 3 trial combining BeiGene's tislelizumab, a PD-1 checkpoint inhibitor, with ImmunityBio's ANKTIVA. The trial is intended to confirm the safety and effectiveness of ANKTIVA combined with CPI therapy which has been demonstrated to improve overall survival in patients with advanced or metastatic NSCLC who have become resistant to immune CPI therapy. ANKTIVA, as a superagonist IL-15, demonstrated its ability to rescue T cells and grow lymphocytes with its proliferative IL-15 stimulatory activity.
- In February 2025, CHOSA partnered with global lung cancer experts to assess platinum sensitivity in over 500 patients with advanced lung cancer in the SPLENDOUR trial. Platinum sensitivity was evaluated using tumor samples from the study, setting the stage for commercialization, clinical guidelines, and regulatory approval.
- In May 2024, Novartis acquired Mariana Oncology, a preclinical-stage biotech firm working on creating new radioligand therapies (RLTs) for high-unmet patient need cancers. The deal bolsters the RLT pipeline of Novartis and increases the research capabilities and clinical supply of the company. Mariana Oncology's pipeline consists of lead optimization and early-stage development programs in solid tumor targets such as breast, prostate, and lung cancer.
- In November 2024, Apollo Cancer Centers initiated the first-ever LungLife Screening Program in India for the early detection of lung cancer. The program aims at people aged 50-80, asymptomatic, smoking history, and have a family history of lung cancer. The highlights are patient registration, consultation with a pulmonologist, pulmonary function test, and low-dose CT scans. Yet, 80% of high-risk individuals have not spoken with their doctors about screening, indicating the urgency for more communication and awareness.
- In October 2023, Bristol Myers Squibb acquired Mirati Therapeutics, enhancing its oncology franchise and broadening its portfolio. The deal translates to a total equity value of $4.8 billion, as well as other value opportunities for Mirati shareholders. The deal introduces KRAZATI, a class-leading KRASG12C inhibitor FDA-approved to treat advanced non-small cell lung cancer patients.
The Report Covers
- Market value data analysis for 2024 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global lung cancer therapeutics market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Global Lung Cancer Therapeutics Market Sales Analysis – Cancer Type | Therapy Type | End User | ($ Million)
• Lung Cancer Therapeutics Market Sales Performance of Top Countries
1.1. Research Methodology
• Primary Research Approach
• Secondary Research Approach
1.2. Market Snapshot
2. Market Overview and Insights
2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Lung Cancer Therapeutics Industry Trends
2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Lung Cancer Therapeutics Market
2.3.1. Competitive Rivalry
2.3.2. Threat of New Entrants
2.3.3. Bargaining Power of Suppliers
2.3.4. Bargaining Power of Buyers
2.3.5. Threat of Substitutes
3. Market Determinants
3.1. Market Drivers
3.1.1. Drivers For Global Lung Cancer Therapeutics Market: Impact Analysis
3.2. Market Pain Points and Challenges
3.2.1. Restraints For Global Lung Cancer Therapeutics Market: Impact Analysis
3.3. Market Opportunities
4. Competitive Landscape
4.1. Competitive Dashboard – Lung Cancer Therapeutics Market Revenue and Share by Manufacturers
• Lung Cancer Therapeutics Product Comparison Analysis
• Top Market Player Ranking Matrix
4.2. Key Company Analysis
4.2.1. AstraZeneca PLC
4.2.1.1. Overview
4.2.1.2. Financial Analysis
4.2.1.3. SWOT Analysis
4.2.1.4. Recent Developments
4.2.2. Boehringer Ingelheim International GmbH.
4.2.2.1. Overview
4.2.2.2. Financial Analysis
4.2.2.3. SWOT Analysis
4.2.2.4. Recent Developments
4.3. Bristol-Myers Squibb Co.
4.3.1.1. Overview
4.3.1.2. Financial Analysis
4.3.1.3. SWOT Analysis
4.3.1.4. Recent Developments
4.4. Novartis AG
4.4.1.1. Overview
4.4.1.2. Financial Analysis
4.4.1.3. SWOT Analysis
4.4.1.4. Recent Developments
4.5. Eli Lilly and Co.
4.5.1.1. Overview
4.5.1.2. Financial Analysis
4.5.1.3. SWOT Analysis
4.5.1.4. Recent Developments
4.6. Key Strategy Analysis
5. Global Lung Cancer Therapeutics Market by Cancer Type
5.1.1. Non-Small Cell Lung Cancer (NSCLC)
5.1.2. Small Cell Lung Cancer (SCLC)
6. Global Lung Cancer Therapeutics Market by Therapy Type
6.1.1. Targeted Therapy
6.1.2. Immunotherapy
6.1.3. Chemotherapy
6.1.4. Radiation Therapy
6.1.5. Others (Combination therapy, and Adjuvant/ Neoadjuvant therapy)
7. Global Lung Cancer Therapeutics Market by End User
7.1.1. Hospitals
7.1.2. Cancer Research Institutes
7.1.3. Specialty Clinics
7.1.4. Homecare Settings
8. Regional Analysis
8.1. North America Lung Cancer Therapeutics Market Sales Analysis – Cancer Type | Therapy Type | End User | ($ Million)
• Macroeconomic Factors for North America
8.1.1. United States
8.1.2. Canada
8.2. Europe Lung Cancer Therapeutics Market Sales Analysis – Cancer Type | Therapy Type | End User | ($ Million)
• Macroeconomic Factors for Europe
8.2.1. UK
8.2.2. Germany
8.2.3. Italy
8.2.4. Spain
8.2.5. France
8.2.6. Rest of Europe
8.3. Asia-Pacific Lung Cancer Therapeutics Market Sales Analysis – Cancer Type | Therapy Type | End User | ($ Million)
• Macroeconomic Factors for Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Rest of Asia-Pacific
8.4. Rest of the World Lung Cancer Therapeutics Market Sales Analysis – Cancer Type | Therapy Type | End User | ($ Million)
• Macroeconomic Factors for the Rest of the World
8.4.1. Latin America
8.4.2. Middle East and Africa
9. Company Profiles
9.1. AbbVie Inc.
9.1.1. Quick Facts
9.1.2. Company Overview
9.1.3. Product Portfolio
9.1.4. Business Strategies
9.2. Amgen Inc.
9.2.1. Quick Facts
9.2.2. Company Overview
9.2.3. Product Portfolio
9.2.4. Business Strategies
9.3. Astellas Pharma Inc.
9.3.1. Quick Facts
9.3.2. Company Overview
9.3.3. Product Portfolio
9.3.4. Business Strategies
9.4. AstraZeneca
9.4.1. Quick Facts
9.4.2. Company Overview
9.4.3. Product Portfolio
9.4.4. Business Strategies
9.5. Bayer AG
9.5.1. Quick Facts
9.5.2. Company Overview
9.5.3. Product Portfolio
9.5.4. Business Strategies
9.6. Boehringer Ingelheim International GmbH.
9.6.1. Quick Facts
9.6.2. Company Overview
9.6.3. Product Portfolio
9.6.4. Business Strategies
9.7. Bristol-Myers Squibb Co.
9.7.1. Quick Facts
9.7.2. Company Overview
9.7.3. Product Portfolio
9.7.4. Business Strategies
9.8. Daiichi Sankyo, Inc.
9.8.1. Quick Facts
9.8.2. Company Overview
9.8.3. Product Portfolio
9.8.4. Business Strategies
9.9. Eli Lilly and Co.
9.9.1. Quick Facts
9.9.2. Company Overview
9.9.3. Product Portfolio
9.9.4. Business Strategies
9.10. F. Hoffmann-La Roche Ltd
9.10.1. Quick Facts
9.10.2. Company Overview
9.10.3. Product Portfolio
9.10.4. Business Strategies
9.11. Fresenius Kabi AG
9.11.1. Quick Facts
9.11.2. Company Overview
9.11.3. Product Portfolio
9.11.4. Business Strategies
9.12. Gilead Sciences, Inc.
9.12.1. Quick Facts
9.12.2. Company Overview
9.12.3. Product Portfolio
9.12.4. Business Strategies
9.13. GlaxoSmithKline plc.
9.13.1. Quick Facts
9.13.2. Company Overview
9.13.3. Product Portfolio
9.13.4. Business Strategies
9.14. Janssen Pharmaceutica NV
9.14.1. Quick Facts
9.14.2. Company Overview
9.14.3. Product Portfolio
9.14.4. Business Strategies
9.15. Johnson & Johnson Services, Inc.
9.15.1. Quick Facts
9.15.2. Company Overview
9.15.3. Product Portfolio
9.15.4. Business Strategies
9.16. Merck KGaA
9.16.1. Quick Facts
9.16.2. Company Overview
9.16.3. Product Portfolio
9.16.4. Business Strategies
9.17. Mylan N.V.
9.17.1. Quick Facts
9.17.2. Company Overview
9.17.3. Product Portfolio
9.17.4. Business Strategies
9.18. Novartis AG
9.18.1. Quick Facts
9.18.2. Company Overview
9.18.3. Product Portfolio
9.18.4. Business Strategies
9.19. Pfizer Inc.
9.19.1. Quick Facts
9.19.2. Company Overview
9.19.3. Product Portfolio
9.19.4. Business Strategies
9.20. Regeneron Pharmaceuticals Inc.
9.20.1. Quick Facts
9.20.2. Company Overview
9.20.3. Product Portfolio
9.20.4. Business Strategies
9.21. SANOFI WINTHROP INDUSTRIE
9.21.1. Quick Facts
9.21.2. Company Overview
9.21.3. Product Portfolio
9.21.4. Business Strategies
9.22. Takeda Pharmaceutical Co. Ltd.
9.22.1. Quick Facts
9.22.2. Company Overview
9.22.3. Product Portfolio
9.22.4. Business Strategies
9.23. Teva Pharmaceutical Industries Ltd.
9.23.1. Quick Facts
9.23.2. Company Overview
9.23.3. Product Portfolio
9.23.4. Business Strategies
1. Global Lung Cancer Therapeutics Market Research And Analysis By Cancer Type, 2023-2031 ($ Million)
2. Global Non-Small Cell Lung Cancer (NSCLC) Lung Cancer Therapeutics Market Research And Analysis By Region, 2023-2031 ($ Million)
3. Global Small Cell Lung Cancer (SCLC) Lung Cancer Therapeutics Market Research And Analysis By Region, 2023-2031 ($ Million)
4. Global Lung Cancer Therapeutics Market Research And Analysis By Therapy Type, 2023-2031 ($ Million)
5. Global Targeted Lung Cancer Therapeutics Market Research And Analysis By Region, 2023-2031 ($ Million)
6. Global Immunotherapy Lung Cancer Therapeutics Market Research And Analysis By Region, 2023-2031 ($ Million)
7. Global Chemotherapy Lung Cancer Therapeutics Market Research And Analysis By Region, 2023-2031 ($ Million)
8. Global Radiation Therapy Lung Cancer Therapeutics Market Research And Analysis By Region, 2023-2031 ($ Million)
9. Global Other Cancer Type Lung Cancer Therapeutics Market Research And Analysis By Region, 2023-2031 ($ Million)
10. Global Lung Cancer Therapeutics Market Research And Analysis By End User, 2023-2031 ($ Million)
11. Global Lung Cancer Therapeutics For Hospitals Market Research And Analysis By Region, 2023-2031 ($ Million)
12. Global Lung Cancer Therapeutics For Cancer Research Institutes Market Research And Analysis By Region, 2023-2031 ($ Million)
13. Global Lung Cancer Therapeutics For Specialty Clinics Market Research And Analysis By Region, 2023-2031 ($ Million)
14. Global Lung Cancer Therapeutics For Homecare Settings Market Research And Analysis By Region, 2023-2031 ($ Million)
15. Global Lung Cancer Therapeutics Market Research And Analysis By Region, 2023-2031 ($ Million)
16. North American Lung Cancer Therapeutics Market Research And Analysis By Country, 2023-2031 ($ Million)
17. North American Lung Cancer Therapeutics Market Research And Analysis By Cancer Type, 2023-2031 ($ Million)
18. North American Lung Cancer Therapeutics Market Research And Analysis By Therapy Type, 2023-2031 ($ Million)
19. North American Lung Cancer Therapeutics Market Research And Analysis By End User, 2023-2031 ($ Million)
20. European Lung Cancer Therapeutics Market Research And Analysis By Country, 2023-2031 ($ Million)
21. European Lung Cancer Therapeutics Market Research And Analysis By Cancer Type, 2023-2031 ($ Million)
22. European Lung Cancer Therapeutics Market Research And Analysis By Therapy Type, 2023-2031 ($ Million)
23. European Lung Cancer Therapeutics Market Research And Analysis By End User, 2023-2031 ($ Million)
24. Asia-Pacific Lung Cancer Therapeutics Market Research And Analysis By Country, 2023-2031 ($ Million)
25. Asia-Pacific Lung Cancer Therapeutics Market Research And Analysis By Cancer Type, 2023-2031 ($ Million)
26. Asia-Pacific Lung Cancer Therapeutics Market Research And Analysis By Therapy Type, 2023-2031 ($ Million)
27. Asia-Pacific Lung Cancer Therapeutics Market Research And Analysis By End User, 2023-2031 ($ Million)
28. Rest Of The World Lung Cancer Therapeutics Market Research And Analysis By Region, 2023-2031 ($ Million)
29. Rest Of The World Lung Cancer Therapeutics Market Research And Analysis By Cancer Type, 2023-2031 ($ Million)
30. Rest Of The World Lung Cancer Therapeutics Market Research And Analysis By Therapy Type, 2023-2031 ($ Million)
31. Rest Of The World Lung Cancer Therapeutics Market Research And Analysis By End User, 2023-2031 ($ Million)
1. Global Lung Cancer Therapeutics Market Share By Cancer Type, 2023 Vs 2031 (%)
2. Global Non-Small Cell Lung Cancer (NSCLC) Lung Cancer Therapeutics Market Share By Region, 2023 Vs 2031 (%)
3. Global Small Cell Lung Cancer (SCLC) Lung Cancer Therapeutics Market Share By Region, 2023 Vs 2031 (%)
4. Global Lung Cancer Therapeutics Market Share By Therapy Type, 2023 Vs 2031 (%)
5. Global Targeted Lung Cancer Therapeutics Market Share By Region, 2023 Vs 2031 (%)
6. Global Immunotherapy Lung Cancer Therapeutics Market Share By Region, 2023 Vs 2031 (%)
7. Global Chemotherapy Lung Cancer Therapeutics Market Share By Region, 2023 Vs 2031 (%)
8. Global Radiation Therapy Lung Cancer Therapeutics Market Share By Region, 2023 Vs 2031 (%)
9. Global Other Therapy Type Lung Cancer Therapeutics Market Share By Region, 2023 Vs 2031 (%)
10. Global Lung Cancer Therapeutics Market Share By End User, 2023 Vs 2031 (%)
11. Global Lung Cancer Therapeutics For Hospitals Market Share By Region, 2023 Vs 2031 (%)
12. Global Lung Cancer Therapeutics For Cancer Research Institutes Market Share By Region, 2023 Vs 2031 (%)
13. Global Lung Cancer Therapeutics For Specialty Clinics Market Share By Region, 2023 Vs 2031 (%)
14. Global Lung Cancer Therapeutics For Homecare Settings Market Share By Region, 2023 Vs 2031 (%)
15. Global Lung Cancer Therapeutics Market Share By Region, 2023 Vs 2031 (%)
16. US Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
17. Canada Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
18. UK Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
19. France Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
20. Germany Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
21. Italy Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
22. Spain Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
23. Russia Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
24. Rest of Europe Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
25. India Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
26. China Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
27. Japan Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
28. South Korea Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
29. Australia and New Zealand Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
30. ASEAN Economies Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
31. Rest of Asia-Pacific Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
32. Latin America Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
33. Middle East and Africa Lung Cancer Therapeutics Market Size, 2024–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
